MarketBeat just released five new trading ideas, but Alpine Immune Sciences wasn't one of them. You'll get all this info in one place. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. And I'm not talking about blockchain, artificial intelligence, 5G, robotics, or the Internet of Things. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. ... the average rating for PINE stock is "Strong Buy." 2020/06/04 (2253KB) Consolidated Financial Results Forecast FY2020. View all of ALPN's competitors. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. The Alpine 4 Technologies stock forecast is 5.433566 USD for 2022 March 11, Friday; and 0.6067 USD for 2026 March 11, Wednesday with technical analysis. View institutional ownership trends for Alpine Immune Sciences. The average price target represents a -100.00% upside from the last price of $27.16. A high-level overview of Alpine 4 Holdings Inc. (ALPP) stock. Alpine 4 Hldgs Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. All times are ET. Price target in 14 days: 15.324 USD. During the day the stock fluctuated 10.83% from a day low at $11.56 to a day high of $12.81. It's the company that's been supplying this key piece of tech to Elon Musk that will shock everyone. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. View Alpine Immune Sciences' earnings history. View analysts' price targets for Alpine Immune Sciences or view top-rated stocks among Wall Street analysts. Since then, ALPN stock has increased by 358.1% and is now trading at $13.33. 2020/04/24 (96KB) Official Announcement Regarding Financial Results Forecasts for the Fiscal Year Ended March 31, 2020. You can opt out at any time. Alpine Income Property Trust (NYSE:PINE) last announced its quarterly earnings data on Wednesday, February 10th. In the past three months, Alpine Immune Sciences insiders have sold more of their company's stock than they have bought. Compare Top Brokerages Here. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Get daily stock ideas top-performing Wall Street analysts. Want to see which stocks are moving? Alpine Immune Sciences does not currently pay a dividend. Alpine Immune Sciences. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. The shares were sold at an average price of $14.25, for a total transaction of $8,550,000.00. Alpine Immune Sciences has received a consensus rating of Buy. 6 analysts have issued 1-year price targets for Alpine Immune Sciences' shares. The biotechnology company earns $-41,850,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. View our earnings forecast for Alpine Immune Sciences. Most stock quote data provided by BATS. Alpine Immune Sciences has received 352 “outperform” votes. What this means: InvestorsObserver gives Alpine 4 Hldgs Inc (ALPP) an overall rank of 34, which is below average. How has Alpine Immune Sciences's share price performed over time and what events caused price changes? Alpine Immune Sciences focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Do Not Sell My Information. To see all exchange delays and terms of use please see disclaimer. An important predictor of whether a stock price will go up is its track record of momentum. CNN Sans™ & © 2016 Cable News Network. Researching Alpine Immune Sciences (NASDAQ:ALPN) stock? Learn more. Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. View which stocks have been most impacted by COVID-19. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Alpine Immune Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021. A rank of 34 means that 66% of stocks appear more favorable to our system. A high percentage of insider ownership can be a sign of company health. All rights reserved. How Much Is Alpine Immune Sciences, Inc. (NASDAQ:ALPN) CEO Getting Paid? Get short term trading ideas from the MarketBeat Idea Engine. How has Alps Alpine's share price performed over time and what events caused price changes? Shares of ALPN can be purchased through any online brokerage account. view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. What this means: Alpine Immune Sciences Inc (ALPN) gets an Overall Rank of 71, which is an above average rank under InvestorsObserver's stock ranking system. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. A Warner Media Company. The biotechnology company had revenue of $1.91 million for the quarter, compared to the consensus estimate of $4.80 million. Please log in to your account or sign up in order to add this asset to your watchlist. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. Vote “Outperform” if you believe ALPN will outperform the S&P 500 over the long term. Learn about financial terms, types of investments, trading strategies and more. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 stock was originally listed at a price of $59.68 in Jun 17, 2015. According to analysts' consensus price target of $19.40, Alpine Immune Sciences has a forecasted upside of 45.5% from its current price of $13.33. The Alpine … Factset: FactSet Research Systems Inc.2019. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. All rights reserved. (Add your “outperform” vote. Wall Street analysts have given Alpine Immune Sciences a "Buy" rating, but there may be better short-term opportunities in the market. View real-time stock prices and stock quotes for a full financial overview. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Their forecasts range from $17.00 to $22.00. Stock analysis for Alpine 4 Holdings Inc (ALPP:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View our full suite of financial calendars and market data tables, all for free. Alpine 4 Technologies (ALPP) stock price prediction is 5.433566 USD. Company insiders that own Alpine Immune Sciences stock include James Paul Rickey, Mitchell Gold, Orbimed Advisors Llc and Robert E Conway. Alpine Immune Sciences does not have a long track record of dividend growth. ALPN stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Samsara BioCapital LLC, and BlackRock Inc.. Company insiders that have sold Alpine Immune Sciences company stock in the last year include Mitchell Gold, and Orbimed Advisors Llc. Find real-time APELY - Alps Alpine Co Ltd stock quotes, company profile, news and forecasts from CNN Business. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. In the short term (2weeks), ALPN's stock price should underperform the market by -3.39%.During that period the price should oscillate between -10.82% and +11.86%. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. Financial Results Forecast of FY2020. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). View insider buying and selling activity for Alpine Immune Sciences or or view top insider-buying stocks. Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. Latest Share Price and Events Stable Share Price : ALPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. 76.10% of the stock of Alpine Immune Sciences is held by insiders. As a group, research analysts forecast that Alpine Income Property Trust, Inc. will post 1.24 EPS for the current fiscal year. Interested in getting the full scoop on ALPP, including earnings and dividends, stock forecast, buy or sell analysis and key stats? You may vote once every thirty days. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer. Price Target. Or you can just type "ALPP news" to get the latest stock news. Alpine Immune Sciences has a market capitalization of $317.29 million and generates $1.74 million in revenue each year. ), Alpine Immune Sciences has received 367 “underperform” votes. If … Identify stocks that meet your criteria using seven unique stock screeners. The consensus among Wall Street research analysts is that investors should "buy" Alpine Immune Sciences stock. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington. Some companies that are related to Alpine Immune Sciences include Mersana Therapeutics (MRSN), Trillium Therapeutics (TRIL), Omeros (OMER), Innoviva (INVA), Indivior (INVVY), Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), BioXcel Therapeutics (BTAI), Zogenix (ZGNX), Dynavax Technologies (DVAX), Veru (VERU), Radius Health (RDUS), Avid Bioservices (CDMO), Enanta Pharmaceuticals (ENTA) and OrganiGram (OGI). If you had invested in Alpine Immune Sciences stock at $59.68, your return over the last 5 years would have been -79.31%, for an annualized return of -27.03%. Get Our PREMIUM Forecast Now, from ONLY $7.49! Based on aggregate information from My MarketBeat watchlists, some companies that other Alpine Immune Sciences investors own include Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Genocea Biosciences (GNCA), OPKO Health (OPK), SCYNEXIS (SCYX), Energy Transfer (ET) and Palatin Technologies (PTN). Alpine Immune Sciences has received 51.04% “underperform” votes from our community. View insider buying and selling activity for Alpine Immune Sciences or view top insider-selling stocks. Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN.". Alpine Immune Sciences' management team includes the following people: “Timed Stocks” are what Silicon Valley legend Jeff Brown calls stocks that, thanks to the federal government, have a preset countdown “timer” attached to their share price… Alpine Immune Sciences has only been the subject of 1 research reports in the past 90 days. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. © American Consumer News, LLC dba MarketBeat® 2010-2021. Alpine Immune Sciences Stock Forecast, ALPN stock price prediction. 52.86% of the stock of Alpine Immune Sciences is held by institutions. Find the latest ALPINE 4 HOLDINGS INC (ALPP) stock quote, history, news and other vital information to help you with your stock trading and investing. Get the latest Alpine Income Property Trust (PINE) stock price quote with real-time news, financials, charts and other important investing information. Learn everything you need to know about successful options trading with this three-part video course. View ALPN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. This NYC Startup Raises $51M to Disrupt the Retirement Industry, 5 Social Security Mistakes to Avoid At All Costs, 7 Mistakes That Will Ruin Your Retirement Income, 7 Retirement Secrets Smart Americans Should Know, You Can Still Buy This "Millionaire Maker" Stock, Bitcoin Up 30,000X -- Here's Your Backdoor In, This Stock Could Be Like Buying Amazon for $3.19. The Alpine 4 Technologies Ltd. stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. FY2019. Alpine Immune Sciences employs 53 workers across the globe. One share of ALPN stock can currently be purchased for approximately $13.33. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings. Alpine Immune Sciences has a P/B Ratio of 8.38. Looking for new stock ideas? Find the latest ALPINE 4 HOLDINGS INC (ALPP) stock discussion in Yahoo Finance's forum. Alpine Immune Sciences's earnings in 2020 is -$27,738,000.On average, 5 Wall Street analysts forecast ALPN's earnings for 2020 to be $-33,108,511, with the lowest ALPN earnings forecast at $-37,104,366, and the highest ALPN earnings forecast at $-29,255,366. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. This is 5.8635% less than the trading day before Friday, 12th Feb 2021. Fundamental company data provided by Zacks Investment Research. Alpine Immune Sciences will be holding an earnings conference call on Thursday, March 18th at 12:00 AM Eastern. $20.83 (14.45% upside) The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. On average, they expect Alpine Immune Sciences' stock price to reach $19.40 in the next twelve months. Alpine Electronics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. The current price of the firm is $4.32. Alpine 4 otc stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. Specifically, they have bought $0.00 in company stock and sold $8,680,100.00 in company stock. 10, Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I, Alpine Immune Sciences to Participate in Upcoming Virtual Healthcare Conferences, Investors Who Bought Alpine Immune Sciences (NASDAQ:ALPN) Shares A Year Ago Are Now Up 318%, Alpine Immune Sciences Announces Executive Leadership Addition and Promotion, Need To Know: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Insiders Have Been Buying Shares, Alpine Immune Sciences to Present at 39th Annual J.P. Morgan Healthcare Conference, Alpine Immune Sciences Appoints Natasha Hernday to Board of Directors, Alpine (ALPN) Looks Good: Stock Adds 7.8% in Session, Alpine Immune Sciences to Participate in Fireside Chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference, Independent Director Robert Conway Just Bought 67% More Shares In Alpine Immune Sciences, Inc. (NASDAQ:ALPN), Alpine Immune Sciences to Participate in Fireside Chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, Analyst Estimates: Here's What Brokers Think Of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) After Its Third-Quarter Report, Alpine Immune Sciences EPS misses by $0.05, misses on revenue, Alpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q3 2020 Results - Earnings Call Transcript, Alpine Immune Sciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update, Alpine Immune Sciences to Report Third Quarter 2020 Financial Results and Provide Corporate Update. Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Alpine Immune Sciences to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update, Alpine Immune Sciences Highlights Poster Presentations At American Association For Cancer Research Apr. S&P 500 3,939.34 ALPP | Complete Alpine 4 Holdings Inc. stock news by MarketWatch. Latest Share Price and Events Stable Share Price : 6770 is not significantly more volatile than the rest of JP stocks over the past 3 months, typically moving +/- 6% a week. Based on 1 analyst offering 12 month price targets for Alpine Immune Sciences in the last 3 months. Signals & Forecast. The official website for Alpine Immune Sciences is www.alpineimmunesciences.com. All Rights Reserved. This price target is based on 1 analysts offering 12 month price targets for Alps Alpine in the last 3 months. Find real-time ALPN - Alpine Immune Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. And the exact second the timer hits zero, the stock can skyrocket (up to a rare 23,200% in a day). 2020/05/08 (748KB) Results Briefing FY2019. Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Learn more. The P/E ratio of Alpine Immune Sciences is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. According to 6 analysts, the average rating for ALPN stock is "Strong Buy." Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Alpine Immune Sciences (ALPN) stock price prediction is 1.894826 USD. Top institutional shareholders include Orbimed Advisors LLC (12.90%), Avidity Partners Management LP (5.24%), Renaissance Technologies LLC (1.93%), Samsara BioCapital LLC (1.68%), Morgan Stanley (1.59%) and Caas Capital Management LP (0.62%). Looking to buy or sell Alpine 4 Technologies Ltd (ALPP)? © This suggests a possible upside of 45.5% from the stock's current price. Alpine 4 Holdings Inc. analyst estimates, including ALPP earnings per share estimates and analyst recommendations. Close price at the end of the last trading day (Tuesday, 16th Feb 2021) of the ALPN stock was $11.72. Forget Tesla. Vote “Underperform” if you believe ALPN will underperform the S&P 500 over the long term. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2019 and/or its affiliates. No recent news for Alpine Immune Sciences Inc. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. There are currently 6 buy ratings for the stock. Interested parties can register for or listen to the call using this link or dial in at Not Available. © 2020 Cable News Network. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Our Accessibility Statement ALPN stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Morgan Stanley, Caas Capital Management LP, Pura Vida Investments LLC, ExodusPoint Capital Management LP, Renaissance Technologies LLC, Vista Capital Partners Inc., and Bank of New York Mellon Corp. Company insiders that have bought Alpine Immune Sciences stock in the last two years include James Paul Rickey, and Robert E Conway. Alpine 4 Holdings stock price forecast* for tomorrow, and next weeks based on the last 30 days. Some negative signals were issued as well, and these may have some influence on the near short-term development. Share your opinion and gain insight from other stock traders and investors. MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Tuesday, November, 17th. This price target is based on 1 analysts offering 12 month price targets for Alps Alpine in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. Earnings for Alpine Immune Sciences are expected to grow in the coming year, from ($1.40) to ($0.65) per share. Alpine 4 Hldgs shows a prevailing Real Value of $4.46 per share. (Add your “underperform” vote.).
Yugioh Toon Deck, Gehalt Informatiker Mit Berufserfahrung, Bestes Mineralwasser Der Welt, Bellissima Pille Gegen Akne, Jobcenter Digital Düsseldorf, Mdr Jump Dingsbums Letzte Folge, Tobias Moretti Jedermann Teufel,